The NextMed Health conference brings together diverse experts with the priorities of accelerating health-based technologies, providing cross-disciplinary collaboration and advancing mindsets. NextMed Health welcomes clinicians, scientists, entrepreneurs, startups, pharma, academics, investors, nurses, patients, public health experts and beyond to address prominent challenges across the healthcare continuum. The conference hopes to engage participants with the most exciting and profound innovators, empowering them to build a better future.
Dr. Keirstead will discuss Immunis’ investigational stem cell secretome product, STEM, highlighting the ongoing Phase 1/2a clinical trial. Immunis has leveraged its leading-edge capabilities in stem cell culture to deliver a trial product of all natural, all human immune modulators that are currently being tested in elderly individuals with muscle atrophy. Dr. Keirstead is honored by the opportunity to speak at a conference dedicated to precision wellness, next generation diagnostics, treatment and global health.
“STEM’s potential to provide benefit in multiple manifestations of age-related and immune-related decline is certainly exciting,” said Dr. Hans S. Keirstead, Chairman of Immunis. “I am honored to share our findings at such an outstanding meeting.”
NextMed Health is an interdisciplinary community with a passion for catalyzing and accelerating novel, human-centric, technology-enabled health. For more information about NextMed Health please visit: www.nextmed.health
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com
Immunis’ FDA-awarded Phase 1/2a clinical trial is an open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in elderly participants with muscle atrophy associated with knee osteoarthritis. Up to 18 patients will be enrolled in the trial and randomly assigned to an IMM01-STEM dose cohort. Treatment will be administered in the form of intramuscular injections twice a week for four weeks (8 injections total). Male or female patients are eligible for the study if they satisfy the following criteria: (1) 50 to 75 years of age at the time of signing the informed consent, (2) have a grade 2 or 3 knee osteoarthritis as defined by Kellgren-Lawrence analyses, (3) have quadricep weakness (<7.5N/kg), (4) can ambulate >50 feet unassisted, (5) are negative for human immunodeficiency virus, hepatitis B surface antigen (HBsAg), and hepatitis C at the Screening Visit and (6) have a body mass index (BMI) of <40kg/m2. For additional information about Immunis’ trial participant qualifications, please visit: www.immunisbiomedical.com
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.